Abstract
A major side effect of anti-neoplastic immunotherapy is the onset of dermatologic toxicities following the administration of several different immunotherapy drugs. We sought to assess the incidence and mortality of anti-neoplastic immunotherapy-associated dermatologic toxicities using a nationally representative sample of United States (US) adults. The National Inpatient Sample database was queried for encounters undergoing anti-neoplastic immunotherapy. Multiple logistic regression models were constructed to analyze incidence of dermatologic toxicity and associated mortality as well as calculate adjusted odds ratios (aOR) after controlling for age, race, sex, household income, and cancer type. Immunotherapy patients demonstrated greater odds of developing pruritus (aOR = 7.59; 95% CI 5.17–11.2; P < 0.001), rash (aOR = 2.81; 95% CI 2.00–3.94, P < 0.001), generalized (aOR = 5.32; 95% CI 3.35–8.43; P < 0.001) and localized (aOR = 2.67; 95% CI 1.01–7.05; P < 0.001) skin eruptions, and vitiligo (aOR = 13.3; 95% CI 5.15–34.4; P < 0.001) compared to patients who did not receive anti-neoplastic immunotherapy. There were no significant differences observed in incidence of non-scarring alopecia (P = 0.7), psoriasis (P = 0.094), and dermatitis (P = 0.9) between the two groups. Patients who underwent immunotherapy were more likely to develop dermatologic toxicity (aOR = 3.93; 95% CI 3.12–4.94; P < 0.001), however, no significant differences in mortality were observed. Patients undergoing anti-neoplastic immunotherapy have an increased risk of developing dermatologic toxicity compared to patients who did not receive anti-neoplastic immunotherapy.
Similar content being viewed by others
Data availability
The data that support the findings of this study are openly available through the Healthcare Cost and Utilization Project by the Agency for Healthcare Research and Quality at https://www.hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp.
References
Havel JJ, Chowell D, Chan TA (2019) The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 19:133–150
Cury-Martins J, Eris APM, Abdalla CMZ, Silva GDB, de Moura VPT, Sanches JA (2020) Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel. An Bras Dermatol 95:221–237
Ellis SR, Vierra AT, Millsop JW, Lacouture ME, Kiuru M (2020) Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features. J Am Acad Dermatol 83:1130–1143
HCUP National Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). 2016–2019.
R Core Team. R: a language and environment for statistical computing. 2022. https://www.r-project.org/. Accessed 15 Aug 2022.
Truong HP, Luke AA, Hammond G, Wadhera RK, Reidhead M, Joynt Maddox KE (2020) Utilization of social determinants of health ICD-10 Z-codes among hospitalized patients in the United States, 2016–2017. Med Care 58:1037–1043
Funding
None.
Author information
Authors and Affiliations
Contributions
All authors contributed to the writing of the manuscript. S.P. prepared tables 1-3. All authors have reviewed the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
None.
Ethical approval
IRB approval status: IRB approval was not required as the study uses a publicly available data source with de-identified information.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Patel, S., Patel, S., Yang, K. et al. Dermatologic toxicities of anti-neoplastic immunotherapy in United States hospitalizations. Arch Dermatol Res 315, 2347–2350 (2023). https://doi.org/10.1007/s00403-023-02623-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00403-023-02623-4